Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

Celltrion Accelerates U.S. Launch of Infliximab-dyyb, a Remicade Biosimilar

Michele B. Kaufman, PharmD, BCGP  |  September 21, 2016

After winning the initial patent infringement lawsuit filed by Janssen, Celltrion Inc. is now shipping Inflectra (infliximab-dyyb), a biosimilar of Remicade (infliximab), to the U.S…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:BiosimilarsCelltrion Inc.FDAFood and Drug Administrationinfliximabinfliximab-dyybOpioids

Is Arthroscopic Meniscal Surgery Effective?

Lara C. Pullen, PhD  |  September 19, 2016

A recent review examined the effectiveness of arthroscopic mensical surgery in treating meniscal injuries. Researchers determined that little evidence exists to support the use of arthroscopic meniscal surgery and more studies that directly compare it with nonoperative treatments are needed…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:arthroscopic meniscal surgerydegenerative meniscal tearkneeknee injuryknee painPhysical Therapysurgery

U.S. Justice Department to Push Prosecutors on Opioids

Reuters Staff  |  September 18, 2016

WASHINGTON (Reuters)—The U.S. Justice Department will enlist federal prosecutors to help fight the nation’s opioid crisis by sharing information on overprescribing doctors and coordinating with public health officials to address addiction, USA Today reported on Friday. “You can’t just have an enforcement strategy alone,” Attorney General Loretta Lynch told the newspaper in an interview. She…

Filed under:AnalgesicsDrug Updates Tagged with:Department of JusticeOpioidsOverdosePain

Abaloparatide Promising for Osteoporosis; NICE Draft Guidelines Include Secukinumab for Ankylosing Spondylitis

Michele B. Kaufman, PharmD, BCGP  |  September 14, 2016

In a clinical trial, subcutaneous abaloparatide has proved effective in treating postmenopausal women with osteoporosis. Also in the U.K., draft guidelines for treating ankylosing spondylitis will recommend the use of secukinumab…

Filed under:Axial SpondyloarthritisBiologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:abaloparatideAnkylosing SpondylitisFDAFood and Drug AdministrationGuidelinesNational Institute for Health and Care ExcellenceOsteoporosis

Research on Ixekizumab in Psoriatic Arthritis and More Presented at EULAR 2016

Thomas R. Collins  |  September 12, 2016

LONDON—Results from the extension phase of a Phase 3 trial for the IL-17A inhibitor ixekizumab in psoriatic arthritis (PsA) show that patients started on placebo, adalimumab and ixekizumab continued to show improvements in arthritis, dactylitis and ethesitis, said Philip Mease, MD, a rheumatologist at Swedish Medical Center University of Washington in Seattle.1 Dr. Mease presented the…

Filed under:ConditionsDrug UpdatesOther Rheumatic ConditionsPsoriatic ArthritisResearch Rheum Tagged with:adalimumabDisease-modifying antirheumatic drugs (DMARDs)EULAREuropean League Against RheumatismixekizumabPsoriatic ArthritisResearchsecukinumabTreatment

Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment

Thomas R. Collins  |  September 8, 2016

LONDON—Josef Smolen, MD, chair of rheumatology at the University of Vienna and former president of the European League Against Rheumatism (EULAR), expressed a “personal disappointment” in the development of useful biomarkers in the treatment of rheumatoid arthritis (RA). Even though a good portion of his life’s work has been researching biomarkers to help with targeting…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:BiomarkersEULAREuropean League Against RheumatismprogressResearchRheumatoid arthritisrheumatologistTreatment

New Research into Rheumatoid Arthritis, Gout Includes Updates on Methotrexate, Biologics, Ultrasound

Thomas R. Collins  |  September 8, 2016

LONDON—From optimizing responses to methotrexate, to the efficacy of biologics, to the need for imaging in assessing remission, the literature, as ever, has been lively with explorations of pressing topics in the treatment and management of rheumatoid arthritis. Josef Smolen, MD, chair of rheumatology at the Medical University of Vienna, reviewed many of the highlights…

Filed under:ConditionsDrug UpdatesGout and Crystalline ArthritisResearch RheumRheumatoid Arthritis Tagged with:Biologicsdrug updateEULAREuropean League Against RheumatismGoutMethotrexatepatient careResearchRheumatoid arthritisrheumatologistTreatmentUltrasound

Lung Complications Closely Entwined with Rheumatologic Diseases

Larry Beresford  |  September 8, 2016

SAN FRANCISCO—Lung involvement is a frequent and often life-threatening manifestation of the connective tissue diseases (CTDs) that are commonly encountered by rheumatologists. A variety of rheumatic diseases can affect the lungs, including systemic sclerosis, rheumatoid arthritis, vasculitis, lupus, polymyositis/dermatomyositis (PM/DM) and Sjögren’s syndrome. A panel presentation on lung disease associated with rheumatic diseases at the…

Filed under:ConditionsResearch Rheum Tagged with:California Rheumatology Alliance 2016lungpatient careResearchRheumatic DiseaserheumatologistTreatment

Sexual Dimorphism Found in Immunologic Profiles of Patients with Ankylosing Spondylosis

Kathy Holliman  |  September 8, 2016

A study that found distinct sexual dimorphism in the immunologic profiles of patients with ankylosing spondylosis (AS) suggests that sex is an important variable to address in future research and may eventually lead to more effective sex-specific therapy for patients with the disease. The research, published in the March 2016 issue of Arthritis & Rheumatology,…

Filed under:Axial SpondyloarthritisConditionsResearch Rheum Tagged with:Ankylosing Spondylitisankylosing spondylosisImmunologypatient careResearchrheumatologysexual dimorphism

Chronic Reactive Arthritis Secondary to Intravesical Bacillus Calmette–Guerin in Bladder Carcinoma

Derick N. Jenkins, MD, Josna Haritha, MD, & Huzaefah Syed, MD  |  September 8, 2016

A 50-year-old man with history of superficial bladder carcinoma presented to our rheumatology clinic for a three-year history of symmetric polyarthralgias. He had undergone multiple transurethral resection of bladder tumor procedures and bacillus Calmette–Guerin (BCG) treatments. Prior to receiving BCG, he was fully functional and employed. Days after receiving his second BCG treatment, he developed…

Filed under:Conditions Tagged with:case reportClinicalDiagnosisoutcomepatient careReactive arthritisrheumatologistTreatment

  • « Previous Page
  • 1
  • …
  • 152
  • 153
  • 154
  • 155
  • 156
  • …
  • 245
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences